SCHEMBL5774496

SCHEMBL5774496

O=C(O)N1CCN(CC(Cc2ccccc2)C2=COCO2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HTT P42858 3/20 0.41
MAPK1 P28482 1/20 0.41
CHRM1 P11229 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
MIF P14174 1/20 0.36
HSD11B1 P28845 1/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656404 0.84 NPC1 (0.43) TSHRSMN1; SMN2POLBL3MBTL1KMT2A
SCHEMBL5750199 0.83 GRIN2D (0.40) TSHRALDH1A1HTTMAPK1CYP3A4
SCHEMBL5750674 0.82 LTA4H (0.41) CHRM1CYP2D6
SCHEMBL3784355 0.81 SIGMAR1 (0.44) TSHRALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL1299631 0.81 SIGMAR1 (0.52) TSHRALDH1A1MAPK1SMN1; SMN2POLB
SCHEMBL2853081 0.81 CHRM1 (0.41) TSHRALDH1A1HTTMAPK1CHRM1
Hydrochloric Acid SCHEMBL1299136 0.80 SIGMAR1 (0.51) TSHRALDH1A1MAPK1SMN1; SMN2POLB
SCHEMBL4380743 0.77 NPC1 (0.51) TSHRALDH1A1HTTMAPK1CHRM1
SCHEMBL1430902 0.77 MIF (0.56) SMN1; SMN2KMT2AMIFHPGDGAA
SCHEMBL8499574 0.76 PRMT5 (0.48) HTTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343780-B1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2006-09-20 EP claimed
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections SMITHKLINE BEECHAM P.L.C. (GB) 2004-04-22 US claimed
EP-1343780-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2003-09-17 EP claimed
WO-2002050061-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-27 WO claimed
EP-1343780-B1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2006-09-20 EP disclosed
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections SMITHKLINE BEECHAM P.L.C. (GB) 2004-04-22 US disclosed
EP-1343780-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2003-09-17 EP disclosed
WO-2002050061-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections MYD88, THPO, PIGO TSHR 2899/4885ALDH1A1 1678/4885HTT 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.